
IgA Nephropathy
Latest News

Latest Videos

CME Content
More News

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.

FDA Accepts, Grants Priority Review to Sibeprenlimab BLA for IgA Nephropathy
With the priority review acceptance of the Biologics License Application, the FDA has assigned a PDUFA target action date of November 28, 2025.

Pregnancies occurring during or after initial C3G presentation were at a greater risk of preeclampsia, prematurity, and renal function decline.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Lerma discusses the current treatment landscape for IgA nephropathy and what role APRIL inhibition may play in treating IgAN.

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.
















































